Skip to main content

InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Publishes Positive Preclinical Findings Related to AV-101

VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has published findings of a preclinical study of its oral NMDA receptor glycine site antagonist, AV-101. The positive findings evaluated the effects of AV-101 in a widely used MPTP nonhuman primate model for reproducing motor complications of Parkinson’s disease (“PD”), including dyskinesia, or sudden uncontrolled movements, observed in PD patients treated with levodopa (“L-Dopa”). The preclinical data indicate a significant reduction of levodopa-induced dyskinesia by AV-101, while maintaining antiparkinsonian activity of levodopa. Vistagen is working to show that AV-101, alone or in combination with FDA-approved oral probenecid, has potential to become an oral treatment alternative for certain CNS disorders involving the NMDAR. The findings from the preclinical study were published in “Cells,” an international, peer-reviewed journal. “While L-Dopa remains the most effective pharmacotherapy for Parkinson’s disease, the occurrence of LID is difficult to manage and drastically interferes with Parkinson’s patients’ quality of life,” said Vistagen CEO Shawn Singh in the press release. “This preclinical study showed that AV-101 reduced LID with no adverse effects of treatment. Dr. Di Paolo has been at the forefront of research in neuropharmacology and treatments for Parkinson’s disease for decades. Her preclinical data from this study are compelling and highlight AV-101’s potential to improve the treatment paradigm for LID associated with Parkinson’s therapy by reducing LID while still maintaining the antiparkinsonian activity of L-Dopa.”

To view the full press release, visit

About VistaGen Therapeutics Inc.

VistaGen is a late clinical-stage CNS-focused biopharmaceutical aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The company is advancing therapeutics with the potential to be faster acting and with fewer side effects and safety concerns than those that are currently available. Vistagen’s clinical-stage candidates are targeting multiple forms of anxiety and depression. PH94B and PH10 belong to a new class of drugs known as pherines, which are odorless and tasteless investigational neuroactive steroids designed with a novel rapid-onset mechanism of action that activates chemosensory neurons in the nasal passages and can impact the olfactory-amygdala neural circuits without systemic uptake or direct activity on CNS neurons in the brain. Vistagen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety and depression — one mind at a time. For more information about the company, please visit

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office

InvestorWire is part of the InvestorBrandNetwork.

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.